Novel yeast bioassay for high-throughput screening of matrix metalloproteinase inhibitors

Applied and Environmental Microbiology

Volumn 77, Issue 24, 2011, Pages 8573-8577

  Diehl, Bjoern ^a   Hoffmann, Thorsten M ^a   Mueller, Nina C ^a   Burkhart, Jens L ^a   Kazmaier, Uli ^a   Schmitt, Manfred J ^a  

^a SAARLAND UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO FUNCTIONALITY; ANTICANCER DRUG; ANTICANCER TREATMENT; CELL WALLS; HIGH-THROUGHPUT SCREENING; HUMAN DISEASE; MATRIX METALLOPROTEINASES; MMP INHIBITOR; PICHIA PASTORIS; RECOMBINANT YEAST CELLS; SIDE-CHAINS; YEAST BIOASSAY; YEAST CELL SURFACE;

BLOOD VESSELS; CELL MEMBRANES; ENZYME INHIBITION; YEAST;

BIOASSAY;

ENZYME INHIBITOR; MATRIX METALLOPROTEINASE; RECOMBINANT PROTEIN;

ASPARTIC ACID; BIOASSAY; ENZYME ACTIVITY; GENE EXPRESSION; INHIBITOR; RECOMBINATION; YEAST;

ARTICLE; DRUG ANTAGONISM; DRUG SCREENING; EVALUATION; GENETICS; HIGH THROUGHPUT SCREENING; HUMAN; ISOLATION AND PURIFICATION; METABOLISM; METHODOLOGY; PICHIA;

DRUG EVALUATION, PRECLINICAL; ENZYME INHIBITORS; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; MATRIX METALLOPROTEINASES; PICHIA; RECOMBINANT PROTEINS;

EID: 83155188271     PISSN: 00992240     EISSN: 10985336     Source Type: Journal    
DOI: 10.1128/AEM.06111-11     Document Type: Article

References (27)

1. Babine, R. E., and S. L. Bender. 1997. Molecular recognition of proteinligand complexes: applications to drug design. Chem. Rev. 97:1359-1472.
2. Breinig, F., et al. 2006. Cell surface expression of bacterial esterase A by Saccharomyces cerevisiae and its enhancement by constitutive activation of the cellular unfolded protein response. Appl. Environ. Microbiol. 72:7140-7147.
3. Corbitt, C. A., J. Lin, and M. L. Lindsey. 2007. Mechanisms to inhibit matrix metalloproteinase activity: where are we in the development of clinically relevant inhibitors? Recent Pat. Anticancer Drug Discov. 2:135-142.
4. Eiden-Plach, A., et al. 2004. Viral preprotoxin signal sequence allows efficient secretion of green fluorescent protein by Candida glabrata, Pichia pastoris, Saccharomyces cerevisiae, and Schizosaccharomyces pombe. Appl. Environ. Microbiol. 70:961-966.
5. Fingleton, B. 2008. MMPs as therapeutic targets-still a viable option? Semin. Cell Dev. Biol. 19:61-68.
6. Gill, S. E., and W. C. Parks. 2008. Metalloproteinases and their inhibitors: regulators of wound healing. Int. J. Biochem. Cell Biol. 40:1334-1347.
7. Gupta, S. P. 2007. Quantitative structure-activity relationship studies on zinc-containing metalloproteinase inhibitors. Chem. Rev. 107:3042-3087.
8. Heussen, C., and E. B. Dowdle. 1980. Electrophoretic analysis of plasminogen activators in polyacrylamide gels containing sodium dodecyl sulfate and copolymerized substrates. Anal. Biochem. 102:196-202.
9. Imai, K., and Y. Okada. 2008. Purification of matrix metalloproteinases by column chromatography. Nat. Protoc. 3:1111-1124.
10. Johnson, W. H., N. A. Roberts, and N. Borkakoti. 1987. Collagenase inhibitors: their design and potential therapeutic use. J. Enzyme Inhib. 2:1-22.
11. Kazmaier, U., and C. Schneider. 1998. Application of the asymmetric chelate- enolate claisen rearrangement to the synthesis of 5-epi-isofagomine. Tetrahedron Lett. 39:817-818.
12. Kazmaier, U., and C. Schneider. 1998. Application of the asymmetric chelate enolate claisen rearrangement to the synthesis of unsaturated polyhydroxylated amino acids. Synthesis 1998(9):1321-1326. doi:10.1055/s-1998-6104.
13. Kazmaier, U., and C. Schneider. 1996. Stereoselective synthesis of unsaturated polyhydroxylated amino acids via ester enolate claisen rearrangement. Synlett 1996(10):975-977. doi:10.1055/s-1996-5637.
14. Kessenbrock, K., V. Plaks, and Z. Werb. 2010. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 141:52-67.
15. Krebs, A., and U. Kazmaier. 1996. The asymmetric ester enolate claisen rearrangement as a suitable method for the synthesis of sterically highly demanding amino acids. Tetrahedron Lett. 37:7945-7946.
16. Lee, M., R. Fridman, and S. Mobashery. 2004. Extracellular proteases as targets for treatment of cancer metastases. Chem. Soc. Rev. 33:401-409.
17. Miller, A., et al. 1997. Inhibition of matrix metalloproteinases: an examination of the S1′ pocket. Bioorg. Med. Chem. Lett. 7:193-197.
18. Mott, J. D., and Z. Werb. 2004. Regulation of matrix biology by matrix metalloproteinases. Curr. Opin. Cell Biol. 16:558-564.
19. Okada, Y., et al. 1990. Matrix metalloproteinase 2 from human rheumatoid synovial fibroblasts. Purification and activation of the precursor and enzymic properties. Eur. J. Biochem. 194:721-730.
20. Porter, J. R., et al. 1994. Potent and selective inhibitors of gelatinase-A 1. Hydroxamic acid derivatives. Bioorg. Med. Chem. Lett. 4:2741-2746.
21. Somerville, R. P., S. A. Oblander, and S. S. Apte. 2003. Matrix metalloproteinases: old dogs with new tricks. Genome Biol. 4:216.
22. Sternlicht, M. D., and Z. Werb. 2001. How matrix metalloproteinases regulate cell behavior. Annu. Rev. Cell Dev. Biol. 17:463-516.
23. Supuran, C. T., and A. Scozzafaca. 2002. Matrix metalloproteinases, p. 35-61. In H. J. Smith and C. Simons (ed.), Proteinase and peptidase inhibition: recent potential targets for drug development. Taylor and Francis, New York, NY.
24. Tu, G., W. Xu, H. Huang, and S. Li. 2008. Progress in the development of matrix metalloproteinase inhibitors. Curr. Med. Chem. 15:1388-1395.
25. Van der Vaart, J. M., R. te Biesebeke, J. W. Chapman, H. Y. Toschka, F. M. Klis, and C. T. Verrips. 1997. Comparison of cell wall proteins of Saccharomyces cerevisiae as anchors for cell surface expression of heterologous proteins. Appl. Environ. Microbiol. 63:615-620.
26. Visse, R., and H. Nagase. 2003. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ. Res. 92:827-839.
27. Whittaker, M., C. D. Floyd, P. Brown, and A. J. Gearing. 1999. Design and therapeutic application of matrix metalloproteinase inhibitors. Chem. Rev. 99:2735-2776.